Trabedersen sodium
Based on 1 publication(s) in Google Scholar
Trabedersen (AP 12009) sodium is an orally active synthetic antisense phosphorothioate oligodeoxynucleotide that selectively targets human TGFβ2 mRNA. Trabedersen sodium blocks TGFβ2 protein production, enters the nucleus without a transfection vector, and exerts dose-dependent antitumor effects. By reversing TGFβ2-induced immunosuppression and enhancing immune cytotoxicity, Trabedersen sodium exhibits significant antiproliferative, antimigratory, and antimetastatic activities, with favorable safety profiles. Trabedersen sodium is widely used in research related to various solid tumors, including anaplastic astrocytoma, glioblastoma, colorectal tumor, and melanoma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 98.81%
- 화학식: C177H217N60Na18O94P17S17
- 분자량:5768.7 (free acid)
-
보관:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications Citing Use of MedChemExpress (MCE) Trabedersen sodium
More
Biological Activity
제품 설명
In Vitro
Trabedersen sodium (1, 5, 10 μM) reduces TGFβ2 secretion by 49-73% and cell proliferation by 24-41%, inhibits migration, and enhances LAK cell-mediated cytotoxicity in human high-grade astrocytoma (III/IV) cells[1].
Trabedersen sodium inhibits TGFβ2 secretion by 43%, reduces cell proliferation by up to 77%, blocks migration, and increases LAK cell cytotoxicity 4-fold in human pancreatic cancer cell lines (Hup-T3, PA-TU 8902)[1].
Trabedersen sodium (1-80 μM; 7 days) potently suppresses TGF-β2 secretion from human pancreatic cancer Hup-T3 cells, with an IC50 of 1.7 μM and complete inhibition at concentrations ≥60 μM after 7 days of treatment[3].
Trabedersen sodium (2.5-80 μM; 7 days) strongly inhibits proliferation of human pancreatic cancer Hup-T3 cells, with an IC50 of 4.6 μM and >90% inhibition at 40 μM after 7 days of treatment[3].
Trabedersen sodium (5 μM; up to 7 days) completely inhibits migration of human pancreatic cancer PA-TU-8902 cells in a spheroid model when treated with 5 μM for up to 7 days[3].
Trabedersen sodium (200 nM, 5 μM; 6 h, variable) efficiently reverses TGF-β2-mediated immunosuppression of human pancreatic cancer Hup-T3 cells, resulting in significantly increased LAK cell-mediated cytotoxicity against Hup-T3 target cells[3].
Trabedersen sodium (10-80 μM) potently inhibits TGF-β2 secretion in human glioblastoma multiforme cells, with 10 μM trabedersen acting to a greater extent than 80 μM trabedersen[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human pancreatic cancer Hup-T3 cells
-
Concentration:1, 10, 20, 60, 80 μM
-
Incubation Time:7 days (with medium replacement on days 2 and 4)
-
Result:Caused a concentration-dependent reduction of TGF-β2 secretion.
Achieved >30% reduction with 1 μM trabedersen.
Achieved >95% reduction with 20 μM trabedersen.
Resulted in no detectable TGF-β2 at concentrations ≥60 μM.
Had an IC50 of 1.7 μM for TGF-β2 secretion inhibition.
-
Cell Line:human pancreatic cancer Hup-T3 cells
-
Concentration:2.5, 10, 20, 40, 60, 80 μM
-
Incubation Time:7 days (with medium replacement on days 2 and 4)
-
Result:Caused a concentration-dependent reduction in Hup-T3 cell number.
Achieved >90% reduction in cell number with 40 μM trabedersen.
Had an IC50 of 4.6 μM for inhibition of Hup-T3 cell proliferation.
In Vivo
Trabedersen (30-1000 mg/kg; intravenous injection; single bolus dose) is well tolerated in mice and rats at single intravenous bolus doses up to 100 mg/kg, with an LD50 value of 706 mg/kg in mice and 1175 mg/kg in rats[1].
Continuous intravenous infusion of Trabedersen sodium at a dose of 1 mg/kg/day is well tolerated in rats and monkeys, whereas continuous infusion at higher doses induces reversible inflammation and tissue damage; intravenous infusion at a dose of 8 mg/kg every other day for 4 weeks is also well tolerated in monkeys[1].
In cynomolgus monkeys, trabedersen sodium (5-160 mg/kg; intravenous infusion; 2 h duration; single dose) is well tolerated at intravenous doses up to 20 mg/kg over a 2-hour infusion with respect to cardiovascular and complement activation endpoints; it is well tolerated at doses below 5 mg/kg with respect to hematological indices[1].
Trabedersen (0.25-50 mg/kg; i.p.; three times per week; approximately 32-35 days) sodium exhibits potent dose-dependent antitumor activity in orthotopic xenograft melanoma mouse models, reduces lung metastasis, and shows evidence of immunomodulatory effects as well as cellular/nuclear uptake; among these, the 50/16 mg/kg dosing regimen significantly reduces the average tumor weight to 0.395 g[2].
Trabedersen sodium significantly reduces the tumor weight, tumor cell proliferation level, tumor vascularization degree, and incidence of lymph node metastasis of primary pancreatic cancer in orthotopic xenograft mouse models[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:New Zealand White rabbits; Cynomolgus monkeys[1]
-
Dosage:1.4 nmol (intrathecal bolus); 50 nmol (intrathecal bolus); 5 nmol/h (continuous intracerebral infusion)
-
Administration:intrathecal; single bolus dose; intracerebral; continuous infusion; 1 week
-
Result:Reported no clinical signs of toxicity after single intrathecal bolus doses of 1.4 nmol or 50 nmol.
Detected no macroscopic drug-related toxicity after continuous intracerebral infusion of 5 nmol/h for 1 week, but histopathology revealed mild-to-moderate leukocyte infiltration near the injection site.
-
Animal Model:Rats; Cynomolgus monkeys[1]
-
Dosage:1 mg/kg/day (continuous intravenous infusion); 4 mg/kg/day (continuous intravenous infusion); 16 mg/kg/day (continuous intravenous infusion); 8 mg/kg (intravenous over 4 h)
-
Administration:intravenous; continuous infusion; 2 weeks (rats); 2-4 weeks (monkeys); intravenous; over 4 h; every other day; 4 weeks
-
Result:Detected no adverse effects in rats or monkeys treated with 1 mg/kg/day continuous intravenous infusion.
Observed evidence of inflammation and tissue damage at higher continuous infusion doses (4 mg/kg/day, 16 mg/kg/day), including increased erythrocyte sedimentation rate, increased activated partial thromboplastin time, decreased platelet counts, increased blood AST levels, decreased albumin and calcium levels, decreased albumin/globulin ratio, and histological lesions in the liver and kidneys; these lesions were almost completely repaired after a 4-week recovery period.
Noted no significant hematological or biochemical changes in monkeys treated with 8 mg/kg intravenous over 4 h every other day for 4 weeks.
-
Animal Model:BALB/c nu/nu mice[2]
-
Dosage:50 mg/kg initial dose followed by 16 mg/kg subsequent doses; 16 mg/kg; 4 mg/kg; 1 mg/kg; 0.25 mg/kg
-
Administration:i.p.; thrice weekly; approximately 32-35 days
-
Result:Reduced mean tumor weight to 0.395 g in mice treated with 50/16 mg/kg regimen compared to controls.
Exhibited dose-dependent reduction in tumor weight and tumor growth at doses of 1 mg/kg, 4 mg/kg, and 16 mg/kg.
Significantly inhibited lung metastasis.
Showed a trend toward fewer monocytic MDSCs in spleens, with no differences in granulocytic MDSCs or NK cells compared to controls.
Demonstrated clear intracellular and intranuclear fluorescence in all tumor sections from mice receiving intratumoral fluorescently labeled trabedersen, confirming cellular and nuclear uptake.
-
Animal Model:BALB/Cnu/nu mice (8-week-old male, orthotopic pancreatic cancer xenograft model)[3]
-
Dosage:50 mg/kg (initial loading dose); 16 mg/kg (maintenance)
-
Administration:i.p.; single initial loading dose on day 2 post-tumor implantation; three times weekly (Monday, Wednesday, Friday)
-
Result:Reduced mean primary tumor.
Significantly decreased tumor cell proliferation.
Reduced tumor vascularization to approximately one-third of control levels (CD31+ vessel area).
Reduced lymph node metastasis incidence from 7 out of 9 to 2 out of 10.
Showed no significant effect on liver metastasis incidence.
Chemical Information
-
Appearance Solid
-
분자량 5768.7 (free acid)
-
화학식 C177H217N60Na18O94P17S17
-
Color White to off-white
-
SMILES
[Trabedersen (sodium)]
-
Synonyms
AP 12009 sodium
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
MedComm (2020)
Transforming Growth Factor Beta2 Promotes Migration and Inhibits the Proliferation of Gastric Cancer Cells by Regulating the pSmad2/3-NDRG1 Signaling Pathway. [Abstract]2025 Mar 27;6(4):e70148. PMID: 40151835
Protocol
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
순도&문서
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[3]. Schlingensiepen KH, et al. Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci. 2011;102(6):1193-1200. [Content Brief]
[4]. Bogdahn U, et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 2011;13(1):132-142. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)